Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas [Phase 2]
Phase 2 study of LN-145 (LN-145-S1) in relapsed or refractory ovarian cancer, triple-negative breast cancer, anaplastic thyroid cancer, oste…
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors. [Phase 2]
Phase II clinical trial evaluating multimodal ablation with systemic drug therapy for advanced solid tumors, currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) [Phase 3]
A Phase 3 trial in low-risk triple-negative early breast cancer is evaluating neoadjuvant sacituzumab govitecan alone versus sacituzumab gov…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer [Phase 2]
A Phase 2 clinical trial is evaluating datopotamab deruxtecan in combination with durvalumab versus datopotamab deruxtecan alone in PD-L1-ne…
-
CLINICAL_TRIALS other · 2025-11-19Clinical Trial Update: Study of AVZO-021 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
This clinical trial update shows AVZO-021 is in Phase 1/2 for advanced solid tumors including HR+/HER2- breast cancer and several gynecologi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) [Phase 2]
Phase 2 trial evaluating pembrolizumab plus lenvatinib in previously treated patients with select solid tumors; results on efficacy and safe…
-
CLINICAL_TRIALS trial_result · 2025-11-17Clinical Trial Update: Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies [Phase 1]
This clinical trial update notes the termination of a Phase 1 study of BDC-3042 as a single agent and in combination with cemiplimab in pati…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery [Phase 2]
A Phase 2 trial testing capecitabine plus pembrolizumab in triple-negative breast cancer after chemo-immunotherapy and surgery is currently …
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression [Phase 1, Phase 2]
Clinical trial update for BT5528-100 (Phase 1/2) in EphA2-expressing advanced solid tumors. The study includes urothelial carcinoma, ovarian…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC [Phase 2]
A Phase 2 clinical trial from UNICANCER evaluating pembrolizumab with chemotherapy or no treatment guided by tumor-infiltrating lymphocytes …
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer [Phase 2]
Phase 2 study updating SKB264 with or without KL-A167 for recurrent/metastatic HER2-negative breast cancer, including triple-negative and HR…
-
CLINICAL_TRIALS trial_result · 2025-11-14Clinical Trial Update: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. [Phase 1]
This Phase 1 trial of FAZ053 as a single agent and in combination with PDR001 in patients with advanced malignancies has been terminated.
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies [Phase 1, Phase 2]
Clinical trial update for BT8009-100 in nectin-4 expressing advanced malignancies (Phase 1/2) with status ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer [Phase 2]
Phase 2 trial OCTANE assesses adjuvant liposomal doxorubicin and carboplatin for early-stage triple-negative breast cancer; the study is cur…
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating atezolizumab plus chemotherapy for patients with early relapsing recurrent triple-negative breast cancer has comple…
-
CLINICAL_TRIALS trial_result · 2025-11-12Clinical Trial Update: Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer [Phase 2]
A Phase 2 trial of abemaciclib for surgically resectable, chemotherapy-resistant triple-negative breast cancer was terminated.
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Neratinib in Combination With Ruxolitinib in Patients With mTNBC [EARLY_Phase 1]
An early-phase trial is investigating the combination of neratinib and ruxolitinib for metastatic triple-negative breast cancer and is curre…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC) [Phase 1]
Phase Ib study evaluating a low-dose oral cyclophosphamide to potentiate axatilimab and retifanlimab in metastatic triple-negative breast ca…
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC [Phase 2]
Phase 2 neoadjuvant trial (PaCT) for locally advanced triple-negative breast cancer has completed with results posted on 2025-11-06.
-
CLINICAL_TRIALS trial_result · 2025-11-06Clinical Trial Update: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors [Phase 1]
This Phase 1 trial update reports termination of NUV-868 as monotherapy and in combination with olaparib or enzalutamide in adults with adva…
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) [Phase 1]
Phase 1 study evaluating Boserolimab (MK-5890) alone and in combination with Pembrolizumab (MK-3475) in adults with advanced solid tumors; t…
-
CLINICAL_TRIALS research · 2025-11-05Clinical Trial Update: Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer [Phase 3]
This update describes a Phase 3 trial evaluating a shorter chemo-immunotherapy regimen that omits anthracyclines for early-stage triple-nega…
-
CLINICAL_TRIALS trial_result · 2025-11-04Clinical Trial Update: A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer [Phase 1, Phase 2]
Phase I/II study evaluating VLS-1488 in adults with advanced cancer; the trial is currently recruiting across multiple solid-tumor indicatio…
-
CLINICAL_TRIALS research · 2025-11-04Clinical Trial Update: A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) [Phase 2]
A Phase II neoadjuvant trial evaluating sacituzumab govitecan plus pembrolizumab in immunochemotherapy-resistant, early-stage triple-negativ…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours [Phase 2]
Phase 2 clinical trial of crizotinib completed in invasive lobular breast cancer, gastric cancer, and triple-negative breast cancer populati…